# Impact of ultrasound cycloplasty on ocular biomechanics and refractive parameters: a comprehensive review

**Authors:** Liping Yang, Jinli Gao, Yuhui Yan, Guitao Shi

PMC · DOI: 10.3389/fmed.2026.1783195 · Frontiers in Medicine · 2026-02-17

## TL;DR

This review examines how ultrasound cycloplasty affects eye structure and vision, finding minimal long-term impact.

## Contribution

The paper provides a comprehensive synthesis of UCP's effects on ocular biomechanics and refractive parameters.

## Key findings

- UCP achieves sustained intraocular pressure reduction.
- Minimal long-term impact on ocular biomechanics or visual function.
- Current evidence highlights gaps requiring further investigation.

## Abstract

Ultrasound cycloplasty (UCP) is a minimally invasive, non-incisional glaucoma treatment that lowers intraocular pressure through high-intensity focused ultrasound–mediated cyclodestruction. Although UCP has been increasingly adopted in clinical practice, and multiple studies have reported its efficacy and safety, evidence regarding its effects on ocular biomechanics and refractive parameters remains limited, leaving critical knowledge gaps in understanding postoperative structural and functional outcomes. This review focuses on these underexplored aspects, synthesizing available clinical and translational studies to identify current limitations and highlight areas requiring further investigation. Overall, existing evidence suggests that UCP achieves sustained intraocular pressure reduction with minimal long-term impact on ocular biomechanics or visual function. By critically integrating these findings, the review aims to fill knowledge gaps, provide insight for clinicians and researchers, and guide optimized patient selection and postoperative monitoring.

## Linked entities

- **Diseases:** glaucoma (MONDO:0005041)

## Full-text entities

- **Genes:** UCP1 (uncoupling protein 1) [NCBI Gene 7350] {aka SLC25A7, UCP}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}
- **Diseases:** cataract (MESH:D002386), IOP (MESH:D064090), astigmatism (MESH:D001251), Glaucoma (MESH:D005901), hyperemia (MESH:D006940), ocular disease (MESH:D005128), POAG (MESH:D005902), instability (MESH:D043171), necrosis (MESH:D009336), anterior chamber (MESH:C535679), blindness (MESH:D001766), PACG (MESH:D015812), injury (MESH:D014947), optic nerve damage (MESH:D020221), hypotony (MESH:D009123), Inflammatory (MESH:D007249), neurotrophic keratopathy (MESH:C562399), visual decline (MESH:D014786), choroidal detachment (MESH:D000080324), phthisis bulbi (MESH:D014397), ocular surface disease (MESH:D010534), HIFU (MESH:C000657744), pseudoexfoliative glaucoma (MESH:D017889), edema (MESH:D004487)
- **Chemicals:** steroids (MESH:D013256)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953110/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953110/full.md

---
Source: https://tomesphere.com/paper/PMC12953110